Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant
Open Access
- 20 April 2005
- journal article
- research article
- Published by Springer Nature in Journal of Immune Based Therapies and Vaccines
- Vol. 3 (1) , 2
- https://doi.org/10.1186/1476-8518-3-2
Abstract
Human papillomaviruses (HPV) are the most common sexually transmitted viruses. Infection of the cervical epithelium by HPVs can lead to the development of cervical cancer. Recent advances in vaccine research have shown that immunization with papillomavirus-like particles (VLPs) containing the major structural viral protein, L1 from HPV 16 can provide protection from the establishment of a chronic HPV 16 infection and related cervical intraepithelial neoplasia (CIN) in baseline HPV 16 naïve women. To better understand the quantitative and qualitative effects of aluminum adjuvant on the immunogenic properties of an HPV 6, 11, 16 and 18L1 VLP vaccine, we used an HPV-specific, antibody isotyping assay and a competitive immunoassay that measures antibodies to neutralizing epitopes to profile sera from rhesus macaques immunized with the HPV L1 VLP vaccine formulated with or without aluminum adjuvant. Immunization with VLPs formulated with the aluminum adjuvant elicited a significantly stronger immune response with higher peak antibody titers both at four weeks post vaccination (12.7 to 41.9-fold higher) as well as in the persistent phase at week 52 (4.3 to 26.7-fold higher) than that of VLPs alone. Furthermore, the aluminum adjuvant formulated HPV VLP vaccine elicited a predominantly T helper type 2 response, with high levels of IgG1 and IgG4 and low levels of IgG2. The vaccine also elicited high levels of serum IgA, which may be important in providing mucosal immunity to impart protection in the anogenital tract. These results show that the HPV 6, 11, 16 and 18 L1-VLP vaccine formulated with Merck aluminum adjuvant elicits a robust and durable immune response and holds promise as a vaccine for preventing cervical cancer.Keywords
This publication has 37 references indexed in Scilit:
- Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy womenVaccine, 2004
- Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in FinlandJournal of General Virology, 2003
- Cervical Cancer Vaccines: Recent Advances in HPV ResearchViral Immunology, 2003
- Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex AssayClinical and Vaccine Immunology, 2003
- Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle VaccineJournal of Virology, 2002
- Neutralization of Human Papillomavirus Type 11 (HPV‐11) by Serum from Women Vaccinated with Yeast‐Derived HPV‐11 L1 Virus‐like Particles: Correlation with Competitive Radioimmunoassay TiterThe Journal of Infectious Diseases, 2001
- Human Papillomavirus Testing for Triage of Women With Cytologic Evidence of Low-Grade Squamous Intraepithelial Lesions: Baseline Data From a Randomized TrialJNCI Journal of the National Cancer Institute, 2000
- Type Specificity and Significance of Different Isotypes of Serum Antibodies to Human Papillomavirus CapsidsThe Journal of Infectious Diseases, 2000
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial NeoplasiaJNCI Journal of the National Cancer Institute, 1993